Pidnarulex: FDA Fast Track to Treat Solid Tumors

Pidnarulex: FDA Fast Track to Treat Solid Tumors

Senhwa Biosciences’ Pidnarulex (CX-5461) has been granted a Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of solid tumors with BRCA1/2, PALB2, and other gene mutations. In patients with solid tumors, specifically breast...